Sei Investments Co. Cuts Holdings in Tango Therapeutics, Inc. $TNGX

Sei Investments Co. lowered its stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) by 40.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,962 shares of the company’s stock after selling 21,965 shares during the period. Sei Investments Co.’s holdings in Tango Therapeutics were worth $669,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the stock. Global Retirement Partners LLC acquired a new position in shares of Tango Therapeutics during the fourth quarter worth about $35,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Tango Therapeutics by 148,800.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company’s stock worth $40,000 after buying an additional 4,464 shares during the period. ANTIPODES PARTNERS Ltd acquired a new stake in Tango Therapeutics in the fourth quarter valued at approximately $40,000. State of Wyoming acquired a new stake in Tango Therapeutics in the first quarter valued at approximately $128,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Tango Therapeutics by 52.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,544 shares of the company’s stock worth $58,000 after acquiring an additional 2,243 shares during the last quarter. Institutional investors and hedge funds own 78.99% of the company’s stock.

Insider Buying and Selling at Tango Therapeutics

In other news, insider Adam Crystal sold 27,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $29.59, for a total value of $798,930.00. Following the transaction, the insider owned 115,743 shares of the company’s stock, valued at approximately $3,424,835.37. The trade was a 18.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 6.50% of the company’s stock.

Tango Therapeutics Stock Performance

Shares of TNGX opened at $25.60 on Friday. Tango Therapeutics, Inc. has a fifty-two week low of $6.25 and a fifty-two week high of $34.39. The firm has a 50-day simple moving average of $28.92 and a 200-day simple moving average of $22.24. The company has a market capitalization of $4.32 billion, a price-to-earnings ratio of -30.12 and a beta of 1.16.

Tango Therapeutics (NASDAQ:TNGX) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.05). Equities research analysts forecast that Tango Therapeutics, Inc. will post -1.34 EPS for the current year.

Analyst Ratings Changes

TNGX has been the subject of several analyst reports. Wall Street Zen cut shares of Tango Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday. HC Wainwright raised their price objective on shares of Tango Therapeutics from $27.00 to $66.00 and gave the company a “buy” rating in a report on Tuesday, June 9th. B. Riley Financial reaffirmed a “buy” rating on shares of Tango Therapeutics in a research report on Monday, June 8th. Citigroup reaffirmed a “buy” rating on shares of Tango Therapeutics in a research report on Monday, April 27th. Finally, Wedbush boosted their target price on shares of Tango Therapeutics from $19.00 to $33.00 and gave the stock an “outperform” rating in a research note on Thursday, May 14th. Thirteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.31.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.